PTCT - PTC Therapeutics - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US69366J2006

Rare Disease, Muscular Dystrophy, Central Nervous System Disorder, Spinal Muscular Atrophy

PTC Therapeutics Inc. is a biopharmaceutical company that specializes in creating life-changing medicines for people with rare and debilitating disorders. With a strong focus on research and development, the company strives to improve the lives of patients and their families worldwide.

The company's portfolio of approved medicines includes Translarna and Emflaza, which are used to treat Duchenne muscular dystrophy, a severe genetic disorder that affects muscle strength and movement. Upstaza is another medicine that treats aromatic l-amino acid decarboxylas (AADC) deficiency, a rare genetic disorder that affects the nervous system. Tegsedi and Waylivra are used to treat other rare diseases, while Evrysdi is a groundbreaking medicine that treats spinal muscular atrophy (SMA), a genetic disorder that affects muscle strength and movement in adults and children.

PTC Therapeutics has a robust pipeline of development-stage products, including Sepiapterin, which is being developed to treat phenylketonuria, a rare genetic disorder that affects the body's ability to break down protein. The company is also working on a splicing platform, PTC518, to treat Huntington's disease, a devastating genetic disorder that affects the brain. Additionally, PTC Therapeutics is exploring ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia, a rare genetic disorder that affects the nervous system, and utreloxastat to treat amyotrophic lateral sclerosis (ALS), a severe neurological disorder.

The company partners with third-party distributors to ensure that its medicines reach patients in need around the world. PTC Therapeutics has collaborations with leading organizations, including F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. Founded in 1998, PTC Therapeutics is headquartered in South Plainfield, New Jersey, and is committed to making a positive impact on the lives of patients and their families.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for PTCT - PTC Therapeutics  - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for PTCT - PTC Therapeutics  - Stock Price & Dividends

PTCT Stock Overview

Market Cap in USD 2,552m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2013-06-20

PTCT Stock Ratings

Growth 5y -20.8
Fundamental -55.4
Dividend 0.00
Rel. Performance vs Sector 0.79
Analysts 3.38/5
Fair Price Momentum 33.43 USD
Fair Price DCF -

PTCT Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

PTCT Growth Ratios

Growth 12m -17.43%
Growth Correlation 12m 17%
Growth Correlation 3m 10%
CAGR 5y -5.87%
CAGR/Mean DD 5y -0.18
Sharpe Ratio 12m -0.32
Alpha vs SP500 12m -39.75
Beta vs SP500 5y weekly 0.96
ValueRay RSI 45.50
Volatility GJR Garch 1y 57.17%
Price / SMA 50 -5.69%
Price / SMA 200 16.12%
Current Volume 537.2k
Average Volume 20d 955.1k

External Links for PTCT Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of PTCT stocks?
As of July 21, 2024, the stock is trading at USD 32.63 with a total of 537,156 shares traded.
Over the past week, the price has changed by -1.92%, over one month by -1.98%, over three months by +28.87% and over the past year by -15.62%.
What are the forecast for PTCT stock price target?
According to ValueRays Forecast Model, PTCT PTC Therapeutics will be worth about 37.6 in July 2025. The stock is currently trading at 32.63. This means that the stock has a potential upside of +15.2%.
Issuer Forecast Upside
Wallstreet Target Price 36.8 12.8
Analysts Target Price 35.4 8.55
ValueRay Target Price 37.6 15.2